Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia.

Publisher: [Oxford, England] Country of Publication: England NLM ID: 0405543 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1942-5546 (Electronic) Linking ISSN: 00256196 NLM ISO Abbreviation: Mayo Clin Proc Subsets: MEDLINE

Publication: Jan. 2012- : [Oxford, England] : Elsevier
Original Publication: Rochester, MN : Mayo Foundation for Medical Education and Research

Blood Glucose/*analysis ; Diabetes Mellitus, Type 2/*drug therapy ; Diabetes Mellitus, Type 2/*epidemiology ; Hypoglycemia/*prevention & control ; Hypoglycemic Agents/*administration & dosage ; Obesity/*epidemiology; Administration, Oral ; Bariatric Surgery/adverse effects ; Bariatric Surgery/methods ; Body Mass Index ; Comorbidity ; Diabetes Mellitus, Type 2/diagnosis ; Dose-Response Relationship, Drug ; Female ; Humans ; Hypoglycemic Agents/adverse effects ; Male ; Obesity/diagnosis ; Obesity/therapy ; Prevalence ; Prognosis ; Risk Assessment ; Safety Management ; Severity of Illness Index ; Treatment Outcome ; United States/epidemiology

Diabetes mellitus (DM) is a major and growing concern in the United States, in large part because of an epidemic of obesity in America and its relation to type 2 DM. In affected patients, postprandial glucose may be an early indicator of glucose intolerance or a prediabetes condition, which may be a better predictor of cardiovascular risk than impaired fasting glucose level. Treating patients who have early signs of hyperglycemia, including elevated postprandial glucose level, with intensive glucose control that does not lead to weight gain, and ideally may be associated with weight reduction, may be vital to preventing or reducing later cardiovascular morbidity and mortality. Because hypoglycemia is an important complication of current DM treatments and may cause acute secondary adverse cardiovascular outcomes, not causing hypoglycemia is mandatory. Given that weight loss can significantly lower cardiovascular risk and improve other cardiovascular risk factors in patients with type 2 DM and that medications are available that can result in weight reduction without leading to hypoglycemia, the successful treatment of patients with type 2 DM should be individualized and should address the complete pathophysiologic process. This review is a hypothesis article that presents arguments against general approaches to the treatment of type 2 DM. An algorithm is presented in which the goal for managing patients with type 2 DM is to lower the blood glucose level as much as possible for as long as possible without causing hypoglycemia. In addition, body weight should ideally be improved, reducing cardiovascular risk factors and avoiding therapeutic inertia.

Diabetes Care. 2010 May;33(5):983-90. (PMID: 20427682)
Expert Rev Endocrinol Metab. 2009 Mar;4(2):119-129. (PMID: 30780853)
Endocr Pract. 2010 Mar-Apr;16(2):244-8. (PMID: 19833577)
Curr Med Res Opin. 2009 Apr;25(4):1019-27. (PMID: 19278373)
N Engl J Med. 2009 Jan 8;360(2):129-39. (PMID: 19092145)
Diabetes Care. 2010 Jan;33 Suppl 1:S11-61. (PMID: 20042772)
Diabetes Care. 2009 Jan;32(1):187-92. (PMID: 19092168)
Diabetes Obes Metab. 2008 May;10(5):376-86. (PMID: 18355324)
Diabetes Care. 2007 Jan;30(1):162-72. (PMID: 17192355)
N Engl J Med. 2005 Dec 22;353(25):2643-53. (PMID: 16371630)
Int J Clin Pract Suppl. 2001 Sep;(123):30-7. (PMID: 11594296)
Nutr Metab Cardiovasc Dis. 2009 Nov;19(9):604-12. (PMID: 19427768)
Diabetes Care. 2010 Jun;33(6):1163-8. (PMID: 20357382)
Diabetologia. 2007 Feb;50(2):259-67. (PMID: 17160407)
Diabetes Care. 2009 Jan;32(1):193-203. (PMID: 18945920)
Diabetes Technol Ther. 2009 Jun;11(6):353-9. (PMID: 19459763)
Diabetologia. 1999 Sep;42(9):1050-4. (PMID: 10447514)
N Engl J Med. 2008 Jul 17;359(3):229-41. (PMID: 18635428)
Ann Intern Med. 2001 Jan 2;134(1):1-11. (PMID: 11187414)
JAMA. 2007 Jul 11;298(2):194-206. (PMID: 17622601)
Endocr Pract. 2006 Jan-Feb;12 Suppl 1:42-6. (PMID: 16627379)
Arch Intern Med. 1999 May 24;159(10):1104-9. (PMID: 10335688)
Diabetes Care. 2009 Feb;32(2):287-94. (PMID: 19017771)
Diabetes Care. 2010 May;33(5):1149-50. (PMID: 20427688)
Lancet. 1998 Sep 12;352(9131):837-53. (PMID: 9742976)
Diabetes Care. 2003 May;26(5):1485-9. (PMID: 12716809)
Lancet. 2005 Oct 8;366(9493):1279-89. (PMID: 16214598)
Ann Intern Med. 2009 Sep 15;151(6):394-403. (PMID: 19620144)
JAMA. 1979 May 11;241(19):2035-8. (PMID: 430798)
Ann Intern Med. 2004 Sep 21;141(6):413-20. (PMID: 15381514)
Lancet. 1999 Aug 21;354(9179):617-21. (PMID: 10466661)
Diabetes Care. 1998 Jul;21(7):1167-72. (PMID: 9653614)
Diabetes Care. 2008 Mar;31(3):511-3. (PMID: 18025407)
Vasc Health Risk Manag. 2006;2(1):69-77. (PMID: 17319471)
Curr Med Res Opin. 2008 Jan;24(1):275-86. (PMID: 18053320)
J Clin Endocrinol Metab. 2003 Jul;88(7):3082-9. (PMID: 12843147)
N Engl J Med. 2008 Jun 12;358(24):2545-59. (PMID: 18539917)
Endocr Pract. 2008 Nov;14(8):993-9. (PMID: 19095598)
Int J Cardiol. 2010 Jan 7;138(1):91-3. (PMID: 18676043)
N Engl J Med. 1998 Jul 23;339(4):229-34. (PMID: 9673301)
Curr Med Res Opin. 2008 Nov;24(11):3009-22. (PMID: 18828960)
Diabet Med. 1990 Mar-Apr;7(3):228-33. (PMID: 2139394)
Diabetes Care. 2006 Jun;29(6):1263-8. (PMID: 16732006)
J Am Coll Nutr. 2003 Oct;22(5):331-9. (PMID: 14559925)
Diabetes Care. 2007 Nov;30(11):2794-9. (PMID: 17698615)
Diabetologia. 2002 Jul;45(7):937-48. (PMID: 12136392)
Expert Opin Pharmacother. 2010 Feb;11(2):269-79. (PMID: 20030567)
Diabetes Care. 1998 Mar;21(3):360-7. (PMID: 9540016)
Diabetes Care. 2007 Jun;30(6):1374-83. (PMID: 17363746)
Circulation. 2010 Aug 24;122(8):844-6. (PMID: 20733112)
Diabetologia. 2007 Jun;50(6):1140-7. (PMID: 17415551)
Int J Clin Pract. 2007 May;61(5):737-47. (PMID: 17493087)
Diabetes. 2009 Apr;58(4):773-95. (PMID: 19336687)
Lancet. 2009 May 23;373(9677):1765-72. (PMID: 19465231)
Diabet Med. 2008 Mar;25(3):245-54. (PMID: 18215172)
Diabetologia. 2009 Jan;52(1):65-73. (PMID: 18985314)
Int J Clin Pract. 2005 Nov;59(11):1345-55. (PMID: 16236091)
Curr Diabetes Rev. 2008 May;4(2):101-9. (PMID: 18473757)
Lancet. 2008 Oct 4;372(9645):1240-50. (PMID: 18782641)
Diabetes Care. 2007 Mar;30(3):753-9. (PMID: 17327355)
Lancet. 2009 Jul 4;374(9683):39-47. (PMID: 19515413)
Diabetes Care. 2004 Aug;27(8):2067-73. (PMID: 15277443)
Diabetes Care. 2008 Mar;31(3):464-9. (PMID: 18039804)
Diabetes Care. 1998 Aug;21(8):1236-9. (PMID: 9702426)
Am Heart J. 2005 Jan;149(1):54-60. (PMID: 15660034)
Am J Epidemiol. 1990 Apr;131(4):633-43. (PMID: 2316495)
Ann Intern Med. 2005 Oct 18;143(8):559-69. (PMID: 16230722)
BMJ. 2000 Aug 12;321(7258):405-12. (PMID: 10938048)
Diabetes Res Clin Pract. 2001 May;52(2):145-52. (PMID: 11311969)
Diabetes Care. 1999 Jun;22(6):920-4. (PMID: 10372242)
Diabetes Care. 2009 May;32(5):834-8. (PMID: 19208917)
N Engl J Med. 2008 Oct 9;359(15):1577-89. (PMID: 18784090)
N Engl J Med. 2008 Jun 12;358(24):2560-72. (PMID: 18539916)
Diabetes. 2009 Nov;58(11):2642-8. (PMID: 19651816)
J Clin Endocrinol Metab. 2006 Mar;91(3):813-9. (PMID: 16352690)
Postgrad Med. 2010 May;122(3Suppl):1-8. (PMID: 20581432)
Diabetologia. 2009 Jul;52(7):1219-26. (PMID: 19373446)
Endocr Pract. 2009 Sep-Oct;15(6):540-59. (PMID: 19858063)

0 (Blood Glucose)
0 (Hypoglycemic Agents)

Date Created: 20101126 Date Completed: 20101220 Latest Revision: 20240409

20240409

PMC2996166

10.4065/mcp.2010.0468

21106867